ALS Prevalence Higher Among Medicare Population, Study Finds

ALS Prevalence Higher Among Medicare Population, Study Finds

Amyotrophic lateral sclerosis (ALS) prevalence in a large group of patients with Medicare coverage was found to be higher than that previously reported in the U.S., according to a study.

Findings also revealed that having ALS was associated with shorter survival than other motor neuron diseases (MND).

The study, “Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics,” appeared in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Data on the incidence, prevalence, and survival of ALS vary by geography and study design. In the U.S., a 2014 report from the National ALS Registry indicated a prevalence of five cases per 100,000 people, in line with global results. Other studies identified older age, lifestyle choices such as smoking, and genetics as potential risk factors for this disease.

In this study, researchers used a validated algorithm to better understand ALS prevalence, patient characteristics, five-year survival, and factors associated with mortality in adults ages 18-90 with Medicare Advantage prescription drug (MAPD) coverage from a single organization.

The analysis used health plan enrollment information, as well as medical, pharmacy, and laboratory claims data between 2007 and 2011.

Of a total of 2,631 individuals with an MND diagnosis, 1,271 (48%) had ALS, 1,157 (44%) were in the “no ALS” category, and 203 (8%) were classified as “possible ALS.”

ALS prevalence was 20.5 per 100,000 over the five-year period and 11.8 per 100,000 in 2011. This is higher than the rate in the 2014 report, the investigators noted, adding that it likely results from the higher proportion of older adults in their study. Another potential explanation is the lack of data on specific cause of death, unlike in the 2014 National ALS Registry findings.

Join our ALS forums: an online community especially for patients with Amyotrophic Lateral Sclerosis.

The prevalence decreased in patients ages 50-59 (11.7 per 100,00 in 2011) and continued to lower in those ages 60-69 (7.9 per 100,000 ), but increased in older patients — 14.3 in ages 70-79 and 18.3  in ages 80-89 per 100,000.

Both the five-year and 2011 prevalence were higher for men — 26.2 and 16.1 per 100,000, respectively, compared with women (15.8 and 10.6 per 100,000, respectively).

The 2,121 patients with 60 days of continuous health plan coverage before index — which refers to the first claim with a diagnosis of motor neuron disease or ALS — were followed through Dec. 31, 2016. Among this group, 958 patients (45%) were classified as ALS, 978 (46%) as no ALS, and 185 (9%) as possible ALS. This subgroup of possible ALS was older than the no ALS category (mean age of 73 vs. 69 years), and had higher proportion of men (63.8% vs. 51.3%) and dual-eligibility for Medicare and Medicaid.

The patients with no ALS before the first medical claim had a greater proportion of diseases of the circulatory, genitourinary, musculoskeletal, and endocrine systems, as well as of cancer, injury, poisoning, and mental illness than the other two groups. This suggests that disease processes in ALS may differ from other MNDs, “presenting significant challenges in differential diagnosis,” according to the researchers.

Having a disorder other than ALS was also associated with more frequent emergency department visits and hospitalizations, while physician office, outpatient visits, and annual use of testing services were more common for those classified as ALS.

Results also showed that ALS patients had the lowest survival rate (19%) through the end of follow-up, compared with 65% in people with no ALS and 98% in those with possible ALS. The median survival time was 388 days for the ALS group, 542 days for the no ALS group, and 1,473 days for the possible ALS group.

After accounting for patients’ baseline characteristics, the team then found that having a classification of ALS was associated with a 2.85 times higher mortality risk compared with the no ALS group.

Other factors also associated with shorter survival included having respiratory and genitourinary diseases, older age, the number of pre-index acute inpatient admissions, and seeing a psychiatrist or neurologist at the index visit.

No patient with possible ALS was classified as ALS during five more years of follow-up.

“Surveillance data from a Medicare population demonstrated a higher prevalence of ALS,” the scientists wrote. “[The] results highlight the need for effective ALS treatment options and resources for patients with ALS.”

Of note, three of the study’s authors are employed by Humana, a health insurance provider for ALS patients.

José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
follow me
×
José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.
follow me
Latest Posts
  • Grant
  • protein clusters, LAT
  • gut microbiota
  • cognitive problems, quality of life

7 comments

  1. Randy says:

    We’re on Medicare BECAUSE of ALS. More wasted money on this silly research that could be put towards finding a cure.

  2. Lori Cameron says:

    As if the multimillion dollar salaries for the executives were not enough, Humana insurance premiums also pay for junk studies.
    This study and article actually raises these questions: is the ALS Society so cozy with Humana and insurance they actually report this bogus study as “news” or is this study actually a false flag to”justify” the huge cuts to Medicare proposed in the current budget?

    Either way, what a waste of dollars that could go for valid research for a cure.

  3. Randy says:

    ALS has been around forever. What happened to the studies from the 1900’s and 2000-2018? Why are we still on Phase 1 with no cure and doing stupid studies like this? Are all of these years wasted? If you don’t meet the criteria in a federally funded study, call your congressman. They forget that our tax dollars are going to the funding. Stop the bullshit studies and wasting money.

  4. Nick says:

    Waste of money yet again. I want to have hope, but it’s hard looking at the facts and evidence when it comes to ALS.
    So many people have died because of this disease, so many waiting for a treatment that truly prelongs your life, doesn’t have to be a cure. Still nothing in sight that can make you live 10+ years with slower disabilities…But hey we’ll have self driving cars soon, we can put people on the moon, but if you get ALS, good luck to you.

  5. Robert Spotswood says:

    Instead of concentrating on the things that are not working eg, muscles, why not concentrate on things that are still working and growing, such as my hair and nails, which are still growing. Start looking in that direction on how they are still growing and incorporate that into looking at ways of getting the muscles working and growing.

  6. Randy says:

    9 years and no new medicine! How about we have a cure for HIV! What happened to all the money made from the ice bucket challenge? More and more people are coming down with ALS and nothing new……!

Leave a Comment

Your email address will not be published. Required fields are marked *